Dale Pfost
General Partner @ Advent Life Sciences
San Francisco Bay Area, United States
Dale Pfost is a Series A investor at Advent Life Sciences in San Francisco Bay Area focused on Health Care and Biotechnology. Dale Pfost joined Advent in 2010. He has more than 25 years of experience as a life science entrepreneur and executive, with expertise in high technology research tools, genomics, diagnostics and therapeutics. Dale's first company, founded while he was in graduate school, was acquired by SmithKline Beckman. He was founding CEO andChairman of Orchid BioSciences, a pioneer in genetic analysis and personalized medicine that Dale and his team built through strategic acquisitions and took public in 2000 (NASDAQ: ORCH). Dale then became founding CEO and Chairman of Acuity Pharmaceuticals, an innovative ophthalmology company that was acquired by OPKO Health (NYSE AMEX: OPK). As CEO of cancer drug developer Receptor BioLogix, Dale readied the company for a successful acquisition by a European biotechnology firm. Earlier in his career, he was co-founder and CEO of Advent-backed Oxford GlycoSciences (IPO on NASDAQ and LSE).
- Total investments:
- 7
- Last investment:
- Lead investor:
- 57%
Last updated:
For AI agents: llms.txt
Industries Dale Pfost invests in
Stages Dale Pfost invests in
Countries Dale Pfost invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (29%)
- Biotechnology 1 (14%)
- Manufacturing 1 (14%)
- Pharmaceutical 1 (14%)
- Information Technology 1 (14%)
Stage
- Series A 1 (14%)
- Series B 1 (14%)
- Series C 1 (14%)
- Funding Round 1 (14%)
- Convertible Note 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Aura Biosciences
|
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives ofpeople with a wide range of cancers that are poorly managed today.The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts. | $30M / Series C / Dec 21, 2017 | |
Vestagen Technical Textiles
|
Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in2009 and Based in Orlando, Florida. | $9.5M / Venture - Series Unknown / Oct 05, 2017 | |
|
Vestagen Technical Textiles
|
Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in2009 and Based in Orlando, Florida. | $7M / Venture - Series Unknown / Feb 08, 2016 | |
|
Vestagen Technical Textiles
|
Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in2009 and Based in Orlando, Florida. | $3.3M / Convertible Note / Sep 09, 2015 | |
|
Aura Biosciences
|
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor-targeted pseudovirions. The company is applying nanotechnology to help fight cancer in the well-studied area of chemotherapeutics and the emerging field of RNAi. By safely eliminating cancer locally, they can treat early and transform the lives ofpeople with a wide range of cancers that are poorly managed today.The company's goal is to treat small ocular melanomas potentially long before the disease progresses and metastasizes to the liver, where it almost always is fatal. Aura Biosciences was founded in 2007 and is headquartered in Cambridge, Massachusetts. | $21M / Series B / Mar 05, 2015 | |
|
Vestagen Technical Textiles
|
Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in2009 and Based in Orlando, Florida. | $7.3M / Series A / Dec 10, 2013 | |
|
Vestagen Technical Textiles
|
Vestagen Technical Textiles develops, manufactures, and markets textile products and technologies. The company has exclusive North American rights to patented Swiss technologies for medical textiles that can be adapted for a variety of uses and applications, from medical uniforms to athletic apparel. Vestagen Technical Textiles was founded in2009 and Based in Orlando, Florida. | $8.3M / Aug 27, 2013 |
Co-Investors
About Advent Life Sciences
Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,
Advent Life Sciences Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andrew J Wood
Venture Partner
|
|||
|
Dale Pfost
General Partner
|
|||
Kaasim Mahmood
General Partner
|
|||
Satish Jindal
General Partner
|
|||
Shahzad Malik
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Dale Pfost invest in?
Dale Pfost invests primarily in Health Care, Biotechnology and Manufacturing startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Dale Pfost?
Public channels for Dale Pfost include LinkedIn and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Dale Pfost last invest?
The most recent investment recorded for Dale Pfost closed in Dec 2017. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
